ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 613

Interim Analysis of Baseline Characteristics and Preferences of Administration Route of Rheumatoid Arthritis Patients Who Are Bio-Naïve or Switched between Advanced RA Treatments; A Multicenter, Prospective, Observational Study

Haner Direskeneli1, Omer Karadag2, Aşkın Ateş3, Abdurrahman Tufan4, Nevsun Inanc1, Suleyman Serdar Koca5, Gozde Yildirim Cetin6, Servet Akar7, Muhammet Cinar8, Sedat Yılmaz8, Neslihan Yilmaz9, Ediz Dalkiliç10, Cemal Bes11, Zeynep Ozbalkan12, Baris Yilmazer13, Ali Şahin14, Emine Duygu Ersozlu15, Mehmet Engin Tezcan16, Nesrin Şen16, Gokhan Keser17, Ilkan Tansoker18, Fatma Basak Hacibedel19, Kerem Helvacioglu19 and Levent Mert Gunay18, 1Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 2Hacettepe University Faculty of Medicine, Ankara, Turkey, 3Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine, Ankara, Turkey, 4Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, 5Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, 6Department of Internal Medicine, Division of Rheumatology, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey, 7Faculty of Medicine, Department of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey, 8Rheumatology Division, Gülhane Training and Research Hospital, Ankara, Turkey, 9Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, 10Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 11Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 12Rheumatology Division, Ankara Numune Training and Research Hospital, Ankara, Turkey, 13Internal Medicine, Rheumatology Division, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey, 14Department of Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey, 15Rheumatology Division, Ministry of Health Adana City Hospital, Adana, Turkey, 16Rheumatology Division, Ministry of Health İstanbul Kartal Training and Research Hospital, Istanbul, Turkey, 17Rheumatology, Ege University Medical Faculty, Izmir, Turkey, 18Medical Department, Pfizer, Istanbul, Turkey, 19Health Economics and Outcomes Research Department, Pfizer, Istanbul, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To describe the baseline characteristics, patient and physician preferences of rheumatoid arthritis patients treated with biologics or targeted therapies in a real world setting.

Methods: This is an interim analysis of a multicenter, prospective, observational study. We have recruited patients who were prescribed advanced RA treatments for the first time (bio-naïve) or needed a switch in their current advanced treatments (bio-experienced). The patients were classified as RA, according to ACR 2010 criteria. The patients will be followed for 12 months and will be evaluated with EQ-5D (EuroQol 5 Dimension), HAQ, DAS28-4(ESR), CQR-19 (Compliance Questionnaire for Rheumatology) and WPAI (Work Productivity and Activity Impairment) every three months. Target recruitment is 590 patients. For this analysis, database was locked by March 2018 with 370 patients.

Results: We have included the data from the baseline visits of 370 moderate to severe RA patients in this analysis. Baseline patient characteristics for demographic findings, disease state and compliance (CQR) are shown in Table 1. Among the bio-naïves, 58% declared that they would prefer using advanced treatments orally after the failure of conventional synthetic DMARDs, while 24% of them preferred SC and 17% IV infusion. Among the bio-experienced patients 46% (n=39) preferred oral intake, 31% (n=26) SC injection and 23% (n=19) IV infusion. In 54.0% of the cases, the drug administration routes in the physicians’ prescriptions were in concordance to the patients’ preference, whereas in 38.4% physicians prescribed drugs with different routes of administration. In 7.6% of the cases, patient preference is not known. In binary logistic regression analyses, patient and physician preferences for the route of administration were independent of baseline characteristics (Table 2).

Conclusion: Oral drug intake is the preferred route of administration for patients and physicians in advanced rheumatoid arthritis treatment. Patient and physician preferences for the route of administration were not related to the demographic or clinical variables.

Table 1: Baseline patient characteristics for demographic findings and disease activity scores.

Sample Size (N)

370

Mean Age (SD)

49,6 (11,8)

Female (%)

76%

Mean HAQ Score (SD)

0,92 (0,64)

Mean DAS28-4(ESR) Score (SD)

4,96 (1,19)

Mean CQR Score (SD)

71,1 (12,1)

Table 2: Binary logistic regression analyses of factors effecting patient’s and physician’s administration route preferences.

INDEPENDENT VARIABLES

p

Patient’s preference

Physician’s preference

Sample Size (N)

351

340

Gender

0.165

0.178

Age

0.337

0.745

Education level

0.998

0.490

Bio-experienced

0.087

0.583

Disease duration

0.427

0.140

DAS28-4 (ESH)

0.138

0.956

HAQ

0.589

0.107

EQ5D VAS

0.211

0.541

Restricted daily activities

0.226

0.122

CQR – surveyed prior to prescription

0.370

0.193


Disclosure: H. Direskeneli, None; O. Karadag, None; A. Ateş, None; A. Tufan, None; N. Inanc, None; S. S. Koca, None; G. Yildirim Cetin, None; S. Akar, None; M. Cinar, None; S. Yılmaz, None; N. Yilmaz, None; E. Dalkiliç, None; C. Bes, None; Z. Ozbalkan, None; B. Yilmazer, None; A. Şahin, None; E. D. Ersozlu, None; M. E. Tezcan, None; N. Şen, None; G. Keser, None; I. Tansoker, Pfizer, Inc., 3; F. B. Hacibedel, Pfizer, Inc., 3; K. Helvacioglu, Pfizer, Inc., 3; L. M. Gunay, Pfizer, Inc., 3.

To cite this abstract in AMA style:

Direskeneli H, Karadag O, Ateş A, Tufan A, Inanc N, Koca SS, Yildirim Cetin G, Akar S, Cinar M, Yılmaz S, Yilmaz N, Dalkiliç E, Bes C, Ozbalkan Z, Yilmazer B, Şahin A, Ersozlu ED, Tezcan ME, Şen N, Keser G, Tansoker I, Hacibedel FB, Helvacioglu K, Gunay LM. Interim Analysis of Baseline Characteristics and Preferences of Administration Route of Rheumatoid Arthritis Patients Who Are Bio-Naïve or Switched between Advanced RA Treatments; A Multicenter, Prospective, Observational Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/interim-analysis-of-baseline-characteristics-and-preferences-of-administration-route-of-rheumatoid-arthritis-patients-who-are-bio-naive-or-switched-between-advanced-ra-treatments-a-multicenter-prosp/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interim-analysis-of-baseline-characteristics-and-preferences-of-administration-route-of-rheumatoid-arthritis-patients-who-are-bio-naive-or-switched-between-advanced-ra-treatments-a-multicenter-prosp/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology